Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012

Ascites is the most common of the three major complications of cirrhosis, the other complications being hepatic encephalopathy and variceal hemorrhage. Cirrhosis is the most common cause of ascites in the United States. Development of ascites may be the first evidence of the presence of cirrhosis. Obesity makes the physical examination less helpful in detecting ascites. Imaging may provide the first evidence of the presence of ascites. Patients with ascites are frequently admitted to hospitals. Effective care of these patients can reduce the frequency of these readmissions. This version of the American Association for the Study of Liver Diseases Practice Guideline is the fourth iteration of this guideline and represents a thorough update of the 2009 version. Introduction

[1]  M. Cappell,et al.  A multicenter, case-controlled study of the clinical presentation and etiology of ascites and of the safety and clinical efficacy of diagnostic abdominal paracentesis in HIV seropositive patients. , 1994, The American journal of gastroenterology.

[2]  H. Shalaby,et al.  Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites. , 2009, World journal of gastroenterology.

[3]  S. J. Park,et al.  Percutaneous peritoneovenous shunt creation for the treatment of benign and malignant refractory ascites. , 2001, Journal of vascular and interventional radiology : JVIR.

[4]  M. Bilodeau,et al.  Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease , 2005, Alimentary pharmacology & therapeutics.

[5]  P. Kamath,et al.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. , 2003, Gastroenterology.

[6]  J. Rundback,et al.  Peritoneal-urinary drainage for treatment of refractory ascites: a pilot study. , 1998, Journal of vascular and interventional radiology : JVIR.

[7]  A. Lok,et al.  Outcomes of patients with chest tube insertion for hepatic hydrothorax , 2009, Hepatology international.

[8]  R. Fontana,et al.  Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis , 1999, American Journal of Gastroenterology.

[9]  D. Rubinstein,et al.  Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. , 1985, Gastroenterology.

[10]  J. C. Hernandez,et al.  Oral Antibiotic Prophylaxis Reduces Spontaneous Bacterial Peritonitis Occurrence and Improves Short-Term Survival in Cirrhosis: A Meta-Analysis , 2009, The American Journal of Gastroenterology.

[11]  B. Runyon,et al.  Cellulitis in Patients with Cirrhosis and Edema: An Under-Recognized Complication Currently More Common than Spontaneous Bacterial Peritonitis , 2008 .

[12]  D. Decker,et al.  Benign and malignant cells in effusions: diagnostic value of image DNA cytometry in comparison to cytological analysis. , 1998, Pathology, research and practice.

[13]  E. Schiff,et al.  Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. , 1989, The New England journal of medicine.

[14]  S. Ahn,et al.  Long‐term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: A randomized prospective study , 2005, Journal of gastroenterology and hepatology.

[15]  Eter,et al.  A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES , 2000 .

[16]  B. Runyon Paracentesis of ascitic fluid. A safe procedure. , 1986, Archives of internal medicine.

[17]  S. Caldwell,et al.  Subumbilical midline vascularity of the abdominal wall in portal hypertension observed at laparoscopy. , 1998, Gastrointestinal endoscopy.

[18]  M. Zuckerman,et al.  A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. , 1991, Gastroenterology.

[19]  J. Villeneuve,et al.  Furosemide‐induced natriuresis as a test to identify cirrhotic patients with refractory ascites , 2001 .

[20]  P. Angeli,et al.  Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites , 1994, Hepatology.

[21]  S. Møller EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[22]  B. Runyon Changing flora of bacterial infections in patients with cirrhosis , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[23]  M. Casas,et al.  Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. , 2010, Journal of hepatology.

[24]  V. Boddi,et al.  Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. , 2006, World journal of gastroenterology.

[25]  G. D’Amico,et al.  Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. , 2005, Gastroenterology.

[26]  B. Runyon,et al.  Optimization of ascitic fluid culture technique. , 1988, Gastroenterology.

[27]  A. Nicolini,et al.  Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites , 2004, Hepatology.

[28]  J. Castellote,et al.  Usefulness and complications of thoracentesis in cirrhotic patients. , 2001, The American journal of medicine.

[29]  P. Messa,et al.  Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. , 2003, Hepato-gastroenterology.

[30]  P. Angeli,et al.  Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial , 2009, Gut.

[31]  A. Albillos,et al.  A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. , 2005, Journal of hepatology.

[32]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[33]  P. Angeli,et al.  Hyponatremia in cirrhosis: Results of a patient population survey , 2006, Hepatology.

[34]  S. Saab,et al.  TIPS versus paracentesis for cirrhotic patients with refractory ascites. , 2006, The Cochrane database of systematic reviews.

[35]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[36]  W. Kim,et al.  Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites , 2003, Hepatology.

[37]  Christian Melot,et al.  Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites , 2010, Hepatology.

[38]  T. Starzl,et al.  Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. , 1973, The New England journal of medicine.

[39]  D. Valla,et al.  Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases , 2001, American Journal of Gastroenterology.

[40]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[41]  K. Reddy,et al.  Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management , 2006, Hepatology.

[42]  P. Kamath,et al.  Performance standards for therapeutic abdominal paracentesis , 2004, Hepatology.

[43]  J. Llach,et al.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. , 1988, Gastroenterology.

[44]  P. Angeli,et al.  Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[45]  A. Gimson,et al.  Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. , 1993, Journal of hepatology.

[46]  B. Runyon Ascites and Spontaneous Bacterial Peritonitis , 2011 .

[47]  R. Loomba,et al.  Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  G. Mancia,et al.  Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites , 1997, Hepatology.

[49]  D. Lebrec,et al.  Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. , 1985, Gastroenterology.

[50]  Shou-Dong Lee,et al.  Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. , 2011, Clinical science.

[51]  J. Meunier,et al.  Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system , 2006, Hepatology.

[52]  H. Rousseau,et al.  Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. , 2004, Gastroenterology.

[53]  M. Merli,et al.  Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis , 2003, American Journal of Gastroenterology.

[54]  J. Ariza,et al.  Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. , 2012, Journal of hepatology.

[55]  K. McTigue,et al.  Reexamining the physical examination for obese patients. , 2011, JAMA.

[56]  M. Pavesi,et al.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study , 2012, Hepatology.

[57]  V. Arroyo,et al.  Restricted use of albumin for spontaneous bacterial peritonitis , 2007, Gut.

[58]  B. Runyon Malignancy-related ascites and ascitic fluid "humoral tests of malignancy". , 1994, Journal of clinical gastroenterology.

[59]  M. Başkol,et al.  Five Days of Ceftriaxone to Treat Culture Negative Neutrocytic Ascites in Cirrhotic Patients , 2003, Journal of clinical gastroenterology.

[60]  B. Runyon,et al.  Choosing the location for non‐image guided abdominal paracentesis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[61]  T. Reynolds,et al.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[62]  R. Fisher,et al.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death , 2004, Hepatology.

[63]  A. Gerbes,et al.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity , 2011, Gut.

[64]  J. Such,et al.  Spontaneous Bacterial Peritonitis , 1997, Seminars in liver disease.

[65]  W. Yasmineh,et al.  Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States , 1996, Hepatology.

[66]  T. Nickolas,et al.  Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis , 2012, Digestive Diseases and Sciences.

[67]  J. Llovet,et al.  Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. , 1996, Gastroenterology.

[68]  B. Runyon Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. , 1986, Gastroenterology.

[69]  V. de Lédinghen,et al.  Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis , 2007, Hepatology.

[70]  J. Such,et al.  Selective intestinal decontamination prevents spontaneous bacterial peritonitis. , 1991, Gastroenterology.

[71]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[72]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[73]  S. Navaneethan,et al.  Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis , 2011, International Urology and Nephrology.

[74]  J. Hoefs,et al.  Ascitic fluid analysis in malignancy‐related ascites , 1988, Hepatology.

[75]  P. Mannucci,et al.  Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No , 2006, Journal of thrombosis and haemostasis : JTH.

[76]  T. Ganiats,et al.  An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. , 1997, Journal of hepatology.

[77]  P. Brissot,et al.  Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. , 2002, Journal of hepatology.

[78]  P. Michl Transjugular Intrahepatic Portosystemic Shunt for Cirrhosis and Ascites: Effects in Patients with Organic or Functional Renal Failure , 2000, Scandinavian journal of gastroenterology.

[79]  R. Poupon,et al.  Improved survival after variceal bleeding in patients with cirrhosis over the past two decades , 2004, Hepatology.

[80]  S. Mizrahi,et al.  Minimally invasive repair of recurrent strangulated umbilical hernia in cirrhotic patient with refractory ascites , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[81]  Y. Amoateng-Adjepong,et al.  Giant Nonpancreatic Pseudocyst Causing Acute Anuria , 2002, Journal of clinical gastroenterology.

[82]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[83]  X. Cussó,et al.  Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. , 1992, Gastroenterology.

[84]  B. Runyon,et al.  Natural history of repaired umbilical hernias in patients with and without ascites. , 1985, The American journal of gastroenterology.

[85]  J. Vinel,et al.  Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Albumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study , 2005, The American Journal of Gastroenterology.

[86]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.

[87]  J. Llach,et al.  Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. , 1990, Gastroenterology.

[88]  M. Weston,et al.  Dialysis in the treatment of renal failure in patients with liver disease. , 1977, Clinical nephrology.

[89]  D. van Duin,et al.  Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  G. Daskalopoulos,et al.  Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. , 1987, Gastroenterology.

[91]  S. Walker,et al.  Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. , 1992, Gastroenterology.

[92]  D. Pateron,et al.  Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage , 1994, Hepatology.

[93]  A. Bhalla,et al.  Midodrine Versus Albumin in the Prevention of Paracentesis-Induced Circulatory Dysfunction in Cirrhotics: A Randomized Pilot Study , 2008, The American Journal of Gastroenterology.

[94]  C. Divino,et al.  Complicated hernia presentation in patients with advanced cirrhosis and refractory ascites: management and outcome. , 2010, Surgery.

[95]  B. Runyon,et al.  Hepatic hydrothorax is a relative contraindication to chest tube insertion. , 1986, The American journal of gastroenterology.

[96]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[97]  F. Wong,et al.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. , 2007, Gastroenterology.

[98]  J. Castellví,et al.  Spontaneous bacterial empyema in cirrhotic patients: A prospective study , 1996, Hepatology.

[99]  M. Navasa,et al.  Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. , 2007, Gastroenterology.

[100]  P. Caraceni,et al.  Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials , 2012, Hepatology.

[101]  A. Lenaerts,et al.  Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. , 2005, Gastroenterologie clinique et biologique.

[102]  E. Christensen,et al.  Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome , 2010, Hepatology.

[103]  B. Runyon A pill a day can improve survival in patients with advanced cirrhosis. , 2007, Gastroenterology.

[104]  T. Reynolds,et al.  Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. , 1986, Gastroenterology.

[105]  M. Melcher,et al.  A novel technique to treat ruptured umbilical hernias in patients with liver cirrhosis and severe ascites. , 2003, Journal of laparoendoscopic & advanced surgical techniques. Part A.

[106]  T. Reynolds,et al.  Left pleural effusion in patients with chronic liver disease and ascites prospective study of 22 cases , 1981, Digestive Diseases and Sciences.

[107]  P. Dykes,et al.  Albumin exchange between plasma and ascitic fluid. , 1968, Clinical science.

[108]  D. Rimm,et al.  Use of magnetic enrichment for detection of carcinoma cells in fluid specimens , 2002, Cancer.

[109]  W. Jiménez,et al.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. , 1987, Gastroenterology.

[110]  L. Forni,et al.  Continuous hemofiltration in the treatment of acute renal failure. , 1997, The New England journal of medicine.

[111]  J. Hoefs,et al.  Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. , 1983, The Journal of laboratory and clinical medicine.

[112]  Y. Bacq,et al.  Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial , 1995, Hepatology.

[113]  M. Kumar,et al.  Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute‐on‐chronic liver failure , 2011, Hepatology.

[114]  P. Angeli,et al.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.

[115]  T. Reynolds,et al.  Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit , 2000, American Journal of Gastroenterology.

[116]  J. Belghiti,et al.  Abdominal wall hernias in the setting of cirrhosis. , 1997, Seminars in liver disease.

[117]  B. Sharma,et al.  Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo , 2011, European journal of gastroenterology & hepatology.

[118]  G. Gasbarrini,et al.  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study , 2007, The Lancet.

[119]  C. K. Nain,et al.  Terlipressin versus albumin in paracentesis‐induced circulatory dysfunction in cirrhosis: A randomized study , 2006, Journal of gastroenterology and hepatology.

[120]  T. Blaschke,et al.  Furosemide disposition in cirrhotic patients. , 1981, Gastroenterology.

[121]  P. Hillenbrand,et al.  Use of Metolazone in the Treatment of Ascites due to Liver Disease , 1971, British medical journal.

[122]  M. Pavesi,et al.  Prognostic importance of the cause of renal failure in patients with cirrhosis. , 2011, Gastroenterology.

[123]  G. Kanel,et al.  Glomerular Tubular Reflux‐A Morphologic Renal Lesion Associated with the Hepatorenal Syndrome , 1984, Hepatology.

[124]  M. Antillon,et al.  Effect of marked peripheral leukocytosis on the leukocyte count in ascites. , 1991, Archives of internal medicine.

[125]  K. Reddy,et al.  The North American Study for the Treatment of Refractory Ascites. , 2003, Gastroenterology.

[126]  D. Yeshurun,et al.  Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis , 1999, American Journal of Gastroenterology.

[127]  S. Sarin,et al.  An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response , 2008, The American Journal of Gastroenterology.

[128]  C. Mélot,et al.  Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. , 2011, Journal of hepatology.

[129]  E. H. Ahrens,et al.  The effect of rigid sodium restriction in patients with cirrhosis of the liver and ascites. , 1949, The Journal of laboratory and clinical medicine.

[130]  M. Pirisi,et al.  The Significance of the Furosemide Test for Predicting Ascites Control by Diuretics in Cirrhotics: A Comparison with Volume Expansion and Octreotide Infusion , 2006, Digestive Diseases and Sciences.

[131]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[132]  M. Navasa,et al.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.

[133]  P. Ginès,et al.  Management of patients with cirrhosis awaiting liver transplantation , 2010, Gut.

[134]  Rosa Gilabert,et al.  Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems , 1998, Hepatology.

[135]  J. McHutchison,et al.  The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites , 1992, Annals of Internal Medicine.

[136]  A. Burroughs,et al.  Surgical Repair of Umbilical Hernias in Cirrhosis With Ascites , 2011, The American journal of the medical sciences.

[137]  B. Runyon Monomicrobial nonneutrocytic bacterascites: A variant of spontaneous bacterial peritonitis , 1990, Hepatology.

[138]  D. Rockey,et al.  Hepatic Hydrothorax , 2014, Medicine.

[139]  M. Antillon,et al.  Ascitic fluid pH and lactate: Insensitive and nonspecific tests in detecting ascitic fluid infection , 1991, Hepatology.

[140]  S. Sarin,et al.  Terlipressin: An Asset for Hepatologists! , 2011, Hepatology.

[141]  R. MacLaren,et al.  Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[142]  W. Jiménez,et al.  Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. , 1996, Gastroenterology.

[143]  J. Hoefs,et al.  Culture‐Negative Neutrocytic Ascites: A Variant of Spontaneous Bacterial Peritonitis , 1984, Hepatology.

[144]  W. Jiménez,et al.  Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. , 2012, Journal of hepatology.

[145]  A. Workman,et al.  A new highly sensitive point of care screen for spontaneous bacterial peritonitis using the leukocyte esterase method. , 2010, Journal of hepatology.

[146]  J. Trotter,et al.  Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[147]  A. Saad,et al.  METABOLIC STUDIES WITH THE DIURETIC TRIAMTERENE IN PATIENTS WITH CIRRHOSIS AND ASCITES. , 1964, The New England journal of medicine.

[148]  E. Keeffe,et al.  Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. , 2001, Journal of hepatology.

[149]  A. Andrealli,et al.  Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[150]  B. Runyon,et al.  The efficacy and safety of ɛ‐aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis , 2006, Alimentary pharmacology & therapeutics.

[151]  W. Jiménez,et al.  A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis , 2005, Hepatology.

[152]  P. Ginès,et al.  Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. , 2010, Journal of hepatology.

[153]  K. Brown,et al.  Hemorrhagic complications of large volume abdominal paracentesis. , 1996, The American journal of gastroenterology.

[154]  C. Yancy,et al.  Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. , 2010, JAMA.

[155]  R. Moreau,et al.  Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[156]  Gyeong a Kim,et al.  Terlipressin and Albumin vs Albumin in Patients with Cirrhosis and Hepatorenal Syndrome: A Randomized Study , 2008 .

[157]  G. Everson,et al.  Chronic Albumin Infusions to Achieve Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular Intrahepatic Portosystemic Shunt (TIPS) , 2005, Digestive Diseases and Sciences.

[158]  V. Arroyo,et al.  Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. , 2006, Gastroenterology.

[159]  J. Kaufman Care of patients with ascites. , 1994, New England Journal of Medicine.

[160]  V. Arroyo,et al.  Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. , 1991, The New England journal of medicine.

[161]  A. Sonnenberg,et al.  Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. , 1997, Gastroenterology.

[162]  Nina Singh,et al.  Trimethoprim-Sulfamethoxazole for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhosis , 1995, Annals of Internal Medicine.

[163]  V. Vilgrain,et al.  Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial , 1996 .

[164]  G. Gerken,et al.  Which patients benefit from hemodialysis therapy in hepatorenal syndrome? , 2004, Journal of Gastroenterology and Hepatology.

[165]  M. Rizzetto,et al.  Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. , 2007, Journal of hepatology.

[166]  H. Kunkel,et al.  Electrolyte studies on patients with cirrhosis of the liver. , 1950, The Journal of clinical investigation.

[167]  F. Czerwiec,et al.  Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. , 2012, Journal of hepatology.

[168]  F. Pruvot,et al.  Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta‐analysis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[169]  Aniruddha M. Deshpande,et al.  Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization , 2003, Annals of Internal Medicine.

[170]  M. Miquel,et al.  Natural history of patients hospitalized for management of cirrhotic ascites. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[171]  A. de Gottardi,et al.  Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[172]  A. Domingo,et al.  Rapid diagnosis of spontaneous bacterial peritonitis by use of Reagent Strips , 2003, Hepatology.

[173]  A. Bhalla,et al.  Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. , 2012, Journal of hepatology.

[174]  R. Andrade,et al.  Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis , 2002, European Journal of Clinical Pharmacology.

[175]  G. Klintmalm,et al.  Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. , 1998, Clinical transplantation.

[176]  Franz Hackl,et al.  Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE‐covered stentgrafts versus bare stents , 2003, Hepatology.

[177]  P. Angeli,et al.  Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost , 2006, Alimentary pharmacology & therapeutics.

[178]  D. Gerber,et al.  Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK) , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[179]  P. Northup,et al.  Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. , 2010, Gastrointestinal endoscopy.

[180]  G. McCaughan,et al.  Iatrogenic incarceration of umbilical hernia in cirrhotic patients with ascites. , 1995, The American journal of gastroenterology.

[181]  J. Cohen,et al.  Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis , 1991, Digestive Diseases and Sciences.